Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis

Hepatology

Volumn 60, Issue 5, 2014, Pages 1541-1550

  García Álvarez, Mónica ^a   Pineda Tenor, Daniel ^a   Jiménez Sousa, María A ^a   Fernández Rodríguez, Amanda ^a   Guzmán Fulgencio, María ^a   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; PEGINTERFERON ALPHA; RIBAVIRIN; ANTIVIRUS AGENT; VITAMIN D;

ARTICLE; DISEASE ASSOCIATION; HEPATITIS C; HUMAN; LIVER FIBROSIS; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SEASONAL VARIATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROTHERAPY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; BLOOD; COMPLICATION; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; VITAMIN D;

EID: 84919970559     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27281     Document Type: Article

References (53)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567.
2. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-S56.
3. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat 2011;18:745-759.
4. Bhagani S. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin. Curr Opin HIV AIDS 2011;6:483-490.
5. Martel-Laferriere V, Bichoupan K, Dieterich DT. Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients. J Clin Gastroenterol 2013;48:106-112.
6. Calvaruso V, Craxi A. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012;32(Suppl 1):2-8.
7. Stokes CS, Volmer DA, Grünhage F, Lammert F. Vitamin D in chronic liver disease. Liver Int 2013;33:338-352.
8. Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012;56:2180-2187.
9. Rahman AH, Branch AD. Vitamin D for your patients with chronic hepatitis C? J Hepatol 2013;58:184-189.
10. Gutierrez JA, Parikh N, Branch AD. Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin Liver Dis 2011;31:387-398.
11. (SACN) SACoN. Update on vitamin D: position statement by the Scientific Advisory Committee on Nutrition. 2007.
12. Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. Association between vitamin D and hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2013;19:5917-5924.
13. Sutton AJ, Abrams KR, Jones DR. An illustrated guide to the methods of meta-analysis. J Eval Clin Pract 2001;7:135-148.
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
15. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol 2007;20(Suppl 1):S3-14.
16. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-605.
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
19. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105-114.
20. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-1573.
21. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006;25:3443-3457.
22. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889-894.
23. Milazzo L, Mazzali C, Bestetti G, Longhi E, Foschi A, Viola A, et al. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. Curr HIV Res 2011;9:186-193.
24. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011;53:1118-1126.
25. Guzman-Fulgencio M, Garcia-Alvarez M, Berenguer J, Jimenez-Sousa MA, Cosin J, Pineda-Tenor D, et al. Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. J Infect 2014;68:176-184.
26. Petta S, Grimaudo S, Marco VD, Scazzone C, Macaluso FS, Cammà C, et al. Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Viral Hepat 2013;20:486-493.
27. Ladero JM, Torrejon MJ, Sanchez-Pobre P, Suarez A, Cuenca F, de la Orden V, et al. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ann Hepatol 2013;12:199-204.
28. Mandorfer M, Reiberger T, Payer BA, Ferlitsch A, Breitenecker F, Aichelburg MC, et al. Low vitamin D levels are associated with impaired virologic response to PEGIFN+RBV therapy in HIV-hepatitis C virus coinfected patients. AIDS 2013;27:227-232.
29. Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, et al. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One 2012;7:e40159.
30. Terrier B, Carrat F, Geri G, Pol S, Piroth L, Halfon P, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011;55:756-761.
31. Mohamed AA, Sabry NA, Abbassi MM, Ibrahim WA, Ali-Eldin ZA. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon. Acta Gastroenterol Belg 2013;76:38-44.
32. Bitetto D, Bortolotti N, Falleti E, Vescovo S, Fabris C, Fattovich G, et al. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. Hepatology 2013;57:925-933.
33. Weintraub SJ, Fleckenstein JF, Marion TN, Madey MA, Mahmoudi TM, Schechtman KB. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. Am J Clin Nutr 2012;96:1025-1031.
34. Terrier B, Jehan F, Munteanu M, Geri G, Saadoun D, Sene D, et al. Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. Rheumatology (Oxford) 2012;51:2083-2090.
35. Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S, et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology 2012;56:1641-1650.
36. Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transplant Int 2011;24:43-50.
37. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
38. Lim LY, Chalasani N. Vitamin d deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep 2012;14:67-73.
39. Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011;60:1728-1737.
40. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010;11:344-349.
41. Petta S, Craxi A. How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver Int 2013;33(Suppl 1):23-29.
42. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011;96:1911-1930.
43. Takeuchi F, Yamamoto K, Katsuya T, Nabika T, Sugiyama T, Fujioka A, et al. Association of genetic variants for susceptibility to obesity with type 2 diabetes in Japanese individuals. Diabetologia 2011;54:1350-1359.
44. Ross AC TC, Yaktine AL, et al. (ed.). Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Washington, DC: National Academies Press; 2011.
45. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010;55:2624-2628.
46. Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010;51:1158-1167.
47. Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011;54:887-893.
48. Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Tsuji K, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat 2014;21:348-356.
49. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011;17:5184-5190.
50. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012;18:800-805.
51. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293.
52. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
53. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.